Pharmaceutical company AstraZeneca has conducted various tests of a drug against the coronavirus (COVID-19) in different patients around the world, and later this month it will publish the results of its research. The pharmacist’s medications have been tested in critically ill patients and in patients prone to collapse of the kidneys or heart due to the disease, and They could prevent this condition in addition to helping to avoid the need for mechanical fans.

We also recommend: They warn about the sale of mouthpieces taken out of the garbage in Mexico

One of AstraZeneca’s investigations is conducted with the inhibitor known as acalabrutinib in severely ill patients in the United States, England, France and Italy. Doctors investigate whether this substance can reduce the risk that these patients are subjected to intubations.

“We are evaluating how the inflammatory response is reduced, the severity of disease progression and avoiding intubation. The clinical study will conclude at the end of May and if the results are positive, we would go to a second phase where Mexico is considered to include seriously ill patients, with the prior authorization of the medical, ethical and bioethics committee, ā€¯commented Alberto Hegewisch, medical director of AstraZeneca in Mexico in an interview.

The drug regulates the mechanisms that cause inflammation in the body, and would block them so that the immune system fights the infection avoiding damage to the tissues.

The second drug tested by AstraZeneca is dapagliflozin, and it was tested in patients who are at increased risk of having a heart attack from the coronavirus infection. “One study showed that it reduces cardiac complications among the population infected with COVID-19 and who have risk factors such as diabetes, a history of heart attack and hypertension,” said the expert.

After the results of the investigations are published, Mexico will be among the countries where the new drugs will be tested, with an approximate date of the end of May.